2023

    1. Variations in the Uptake of Active Surveillance for Prostate Cancer and Its Impact on Outcomes. Ahlberg MS, Garmo H, Holmberg L, Bill-Axelson A. Eur Urol Open Sci. 2023 May. Sammafattning
    2. Risks of alcohol and drug use disorders in prostate cancer survivors: a national cohort study. Crump C, Stattin P, Brooks JD, Sundquist J, Edwards AC, Sieh W, Sundquist K. JNCI Cancer Spectr. 2023 Jul. Sammanfattning Fulltext
    3. Stora regionala skillnader i behandlingen av prostatacancer. Stattin P, Gedeborg, R. Debatt, Läkartidningen dec 2023 Fulltext
    4. Risks of Depression, Anxiety, and Suicide in Partners of Men with Prostate Cancer: A National Cohort Study. Crump C, Stattin P, Brooks JD, Sundquist J, Edwards AC, Sundquist K, Sieh W. J Natl Cancer Inst. 2023 Dec. Sammanfattning
    5. Prognosis of Gleason Score 9-10 Prostatic Adenocarcinoma in Needle Biopsies: A Nationwide Population-based Study. Egevad L, Micoli C, Samaratunga H, Delahunt B, Garmo H, Stattin P, Eklund M. Eur Urol Oncol. 2023 Nov Sammanfattning  Fulltext
    6. Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden. Gedeborg R, Sandin F, Thellenberg-Karlsson C, Styrke J, Franck Lissbrant I, Garmo H, Stattin P. Scand J Urol. 2023 Nov. Sammanfattning
    7. Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists. Bonde TM, Garmo H, Stattin P, Nilsson P, Gunnlaugsson A, Swanberg D, Robinson D. Acta Oncol. 2023 Oct.   Sammanfattning Fulltext
    8. Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy. Corsini C, Garmo H, Orrason AW, Gedeborg R, Stattin P, Westerberg M, JAMA Netw Open. 2023 Oct.       Sammanfattning Fulltext
    9. Frequency of Biopsy and Tumor Grade Before vs After Introduction of Prostate Magnetic Resonance Imaging. Robinson D, Abdulkareem R, Nasrollah D, Ljung A, Hintze P, Wallby S, Ståhlbrandt H, Frennvall T, Styrke J, Stattin P, Garmo H. JAMA Netw Open. 2023 Aug.                       Sammanfattning Fulltext
    10. Risk of colorectal adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer; a nationwide cohort study. Shore R, Zhang J, Ye W, Stattin P, Lindblad M. Cancer Causes Control. 2023 Jun. Sammanfattning. Fulltext
    11. Long-term Risks of Depression and Suicide Among Men with Prostate Cancer: A National Cohort Study. Crump C, Stattin P, Brooks JD, Sundquist J, Bill-Axelson A, Edwards AC, Sundquist K, Sieh W. Eur Urol. 2023 May. Sammanfattning.
    12. Jochems SHJ, Fritz J, Häggström C, Stattin P, Stocks T. Prediagnostic markers of insulin resistance and prostate cancer risk and death: A pooled study. Cancer Med. 2023 April. Sammanfattning. Fulltext
    13. Garcia-Albeniz X, Stattin P, Westerberg M, Weinrib R, Sandstrom P, Vassilev Z. Design Considerations for Observational Studies of Drugs for Advanced Cancer. Pharmacoepidemiol Drug Saf. 2023 Mar. Sammanfattning.
    14. Westerberg M. Estimation in discrete time coarsened multivariate longitudinal models. Stat Methods Med Res. 2023 Feb. Sammanfatting. Fulltext
    15. George G, Garmo H, Adolfsson J, Elf K, Gedeborg R, Holmberg L, Stattin P, Styrke J, Van Hemelrijck M. Use of Antiepileptic Drugs and Risk of Prostate Cancer: A Nationwide Case-Control Study in Prostate Cancer Data Base Sweden. J Oncol. 2023 Feb. Sammanfattning. Fulltext
    16. Sun M, Fritz J, Häggström C, Bjørge T, Nagel G, Manjer J, Engeland A, Zitt E, van Guelpen B, Stattin P, Ulmer H, Stocks T. Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study. J National Cancer Institute. 2023 Jan. Sammanfattning. Fulltext